Form 4: RIGL CFO Sells Shares for Tax Obligations

Rigel Pharmaceuticals' EVP & CFO, Dean L. Schorno, disposed of 5,488 common shares to cover tax withholding, retaining 59,247 shares.

Summary

• Dean L. Schorno, Executive Vice President and Chief Financial Officer of Rigel Pharmaceuticals Inc. (RIGL), reported an insider transaction.
• On February 2, 2026, Schorno disposed of 5,488 shares of common stock.
• The disposition was made at a price of $36.01 per share.
• This transaction was coded 'F', indicating a disposition to the issuer to satisfy tax withholding obligations.
• Following this transaction, Schorno directly beneficially owns 59,247 shares of common stock.
• The reported beneficial ownership includes 500 shares acquired under the Issuer's stock purchase plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for executive compensation and tax planning, and not indicative of a change in company fundamentals or insider sentiment.

Positives

• The transaction represents a routine disposition of shares to cover tax withholding obligations, which is a common practice for executives receiving equity compensation.

Negatives

• The disposition of shares, while routine for tax purposes, reduces the direct beneficial ownership of a key executive.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those coded 'F' for tax withholding, are common occurrences in the biotechnology and pharmaceutical industries as part of executive compensation plans. Such routine transactions are generally not indicative of broader industry trends or specific company performance shifts.

Related Party Transactions

• The disposition of shares was made to the issuer (Rigel Pharmaceuticals Inc.) to satisfy tax withholding obligations, which is a standard transaction between an executive and their company related to equity compensation.

Stakeholder Impact

• Shareholders may note a slight reduction in direct insider ownership, but the non-discretionary nature of the sale for tax purposes typically mitigates concerns about management's confidence in the company.

Key Dates

Recommendation

The reported transaction is a routine disposition of shares by an executive to satisfy tax withholding obligations related to equity compensation. It does not reflect a discretionary sale based on a change in company outlook or performance, and therefore, does not warrant a change in investment recommendation.

Keywords

RIGL, Rigel Pharmaceuticals, Dean L. Schorno, Form 4, insider transaction, CFO, tax withholding, equity compensation